Back to today’s briefing

Story perspectives

FDA Approves EGRIFTA WR: New Hope for HIV Patients

3/26/2025

35 6

Summary

Story summary

Theratechnologies Inc. has made a significant breakthrough with the FDA's approval of EGRIFTA WR, a new weekly injectable formulation of tesamorelin designed to combat excess abdominal fat in HIV patients. This innovative treatment not only simplifies dosing but also promises to enhance the management of lipodystrophy, addressing critical gaps in HIV care.

1 of 1

Story summary

Theratechnologies Inc. has made a significant breakthrough with the FDA's approval of EGRIFTA WR, a new weekly injectable formulation of tesamorelin designed to combat excess abdominal fat in HIV patients. This innovative treatment not only simplifies dosing but also promises to enhance the management of lipodystrophy, addressing critical gaps in HIV care.